Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
FOSTER CITY, Calif. and DURHAM, NC, Sept 12, 2018 – Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to…
Penn Announces Publication of Clinically Relevant Genome Editing in Primates Using Precision's ARCUS Platform
Durham, NC July 09, 2018 – The University of Pennsylvania’s Perelman School of Medicine announced today that researchers from Jim Wilson’s Gene Therapy Program have found that using…
Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs
DURHAM, North Carolina, USA, June 26 2018 –Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS®…
Precision BioSciences CSO to Join Gene Therapy Session at DIA 2018
DURHAM, North Carolina, USA, June 20 2018 – Precision BioSciences CSO Derek Jantz will present and join a panel discussion during the DIA (Drug Information Association) 2018 conference session #285,…
Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
DURHAM, North Carolina, USA, May 14 2018 – Precision BioSciences, the ARCUS genome editing company with novel product development programs in gene therapy, cancer immunotherapy and non-GMO food,…
Precision BioSciences Announces Appointment of Gene Liau, Ph.D. and Bruce McCreedy, Ph.D. to Management Team
RESEARCH TRIANGLE PARK, North Carolina, September 2nd, 2015 – Precision BioSciences, the genome editing company, today announced two key additions to the executive team – Gene Liau, Ph.D., as Senior…